Background: To investigate the clinical efficacy of apatinib in combination with oxaliplatin + 5-fluorouracil + leucovorin in clinical chemotherapy for the advanced gastric cancer. Materials and Methods: Between June 2016 and December 2018, we enrolled a total of 92 patients with advanced gastric cancer who were receiving 4500 cGy of radiation through the 5 weeks after resection of adenocarcinoma, and divided them into two groups as per the treatment strategies, with 46 patients in each group. Patients in the control group underwent the regular chemotherapy (oxaliplatin + 5-fluorouracil + leucovorin), while those in the observation group would additionally receive the medication of apatinib. We compared the efficacy, changes in the levels of high-sensitivity C-reactive protein (hs-CRP) and Tumor necrosis factor (TNF-α) in serum, prognosis and adverse reactions between two groups, or before and after treatment. Results: In the observation group, the total effectiveness rate was higher than that in the control group. Also, after treatment, significant decreases were found in levels of high-sensitivity C-reactive protein and TNF-α in serum of patients in the observation group, more evident than those in the control group. Moreover, progression-free survival and total survival durations of patients were significantly longer than those in the control group, while the incidence rate of adverse reaction was reduced sharply (all P < 0.05). Conclusion: our study showed that apatinib combination with oxaliplatin + 5-fluorouracil + leucovorin seems to have promising efficacy, and is worthy of being studied as a new regimen of gastric cancer treatment.